Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab for extramedullary disease in relapsed or refractory multiple myeloma
jRCTs031190045Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: extramedullary plasmacytoma response. Started Dec 2018; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs031190045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190045.